

Table 2. MAFLD prevalence and COVID-19 clinical outcomes.

Author/ Year	MAFLD Prevalence/100,000 (95% CI)	COVID-19 Severity	ICU Admission	Mortality
Bramante et al., 2020 <sup>22</sup>	0.06 (0.05-0.06)	MAFLD and COVID-19 severity, OR: 4.7 (3.81; 5.92), p < 0.01	NA	OR: 0.99 (0.54; 1.77) p = 0.94
Mahamid et al., 2020 <sup>23</sup>	1.00 (0.95-1.00)	MAFLD and COVID-19 severity OR: 3.57 (1.22; 14.45) p = 0.003	NA	NA
Targher et al., 2020 <sup>24</sup>	0.30 (0.25-0.36)	MAFLD low FIB-4: 1.21 (0.46; 3.14), p = 0.701 MAFLD intermediate/high FIB-4: OR: 4.68 (2.31; 9.49) p < 0.001	NA	NA
Targher et al., 2020 <sup>25</sup>	0.17 (0.14-0.22)	Presence of metabolic deregulation (DM2) associated with COVID-19 severity OR: 3.83 (2.06-7.13), p = 0.001	NA	NA
Zhou et al., 2020 <sup>26</sup>	0.28 (0.24-0.34)	MAFLD and COVID-19 severity Younger patients (60 yrs and younger): OR: 3.97 (1.89; 8.35), p < 0.001 Older patients (60 yrs and older): OR: 0.72 (0.24; 2.15), p = 0.55	NA	NA
Zhou et al., 2020 <sup>27</sup>	0.50 (0.40-0.60)	MAFLD and COVID-19 severity OR: 3.65 (1.31; 10.16) p = 0.01	NA	NA
Zheng et al., 2020 <sup>28</sup>	0.31 (0.25-0.37)	Obesity and COVID-19 severity in MAFLD patients OR: 5.77 (1.19; 27.91) <sup>#</sup> p = 0.029	NA	NA
Chen et al., 2020 <sup>29</sup>	0.52 (0.47-0.57)	MAFLD and COVID-19 severity OR: 0.21 (0.19, 0.61) p = 0.30	OR: 1.25 (0.82; 1.91) p = 0.31	MAFLD and COVID-19 mortality OR: 0.61 (0.35, 1.06) p = 0.08
Gao et al., 2021 <sup>32</sup>	0.02 (0.01-0.06)	MAFLD and COVID-19 severity OR: 1.11 (1.04; 1.19), p = 0.001	NA	NA
Forlano et al., 2021 <sup>31</sup>	0.32 (0.25-0.39)	NR	OR: 0.86 (0.39; 1.88) p = 0.005	OR: 0.93 (0.48; 1.80) p = 0.0059
Gao et al., 2020 <sup>30</sup>	0.50 (0.42-0.58)	OR: 2.91 (1.31; 6.47)	NA	NA
Marjot et al., 2021 <sup>33</sup>	0.24 (0.21-0.26)	NR	NA	OR: 0.55 (0.38; 0.80) p = 0.005
Sarin et al., 2020 <sup>34</sup>	0.28 (0.23-0.32)	NR	NA	NA
Parlak et al., 2021 <sup>35</sup>	0.16 (0.12-0.20)	OR: 3.81 (1.97; 7.37)	NA	OR: 4.52 (1.44; 14.18) p = 0.05
Gao et al., 2021 <sup>36</sup>	0.50 (0.41-0.59)	OR: 4.22 (1.45-12.22)	NA	NA
Hashemi et al., 2020 <sup>37</sup>	0.15 (0.12-0.19)	NR	OR: 1.93 (1.10; 3.40) p = 0.0095	OR: 0.27 (0.058; 2.80) p = 0.05
Lopez-Mendez et al., 2020 <sup>38</sup>	0.43 (0.35-0.51)	NR	Liver fibrosis and COVID-19 ICU admission OR: 1.74 (1.13; 2.68) <sup>°</sup> p = 0.023	MAFLD and COVID-19 mortality OR: 5.29 (1.46; 19.23) p = 0.007
Kim et al., 2021 <sup>39</sup>	0.53 (0.49-0.56)	MAFLD and COVID-19 severity HR: 0.55 (0.39; 0.80), p = 0.001	NA	NA
Huang et al., 2020 <sup>40</sup>	0.31 (0.25-0.36)	OR: 6.13(2.26; 16.65)	NA	NA
Ji et al., 2020 <sup>41</sup>	0.38 (0.31-0.45)	MAFLD and COVID-19 severity OR: 3.57 (1.22; 14.48), p = 0.003	NA	NA

Abbreviations: MAFLD: metabolic-associated fatty liver disease, NAFLD: non-alcoholic fatty liver disease, BMI: body mass index, SARS-CoV-2: severe acute respiratory syndrome coronavirus-2, OR: odds ratio, CI: confidence interval, FIB: fibrosis score.